Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Medicines Prevent Cancer Recurrence: New breast cancer drug greatly reduces recurrence and death (5 to 10 years after diagnosis in postmenopausal women)  
  • Approximately one third of men diagnosed with prostate cancer will opt for surgical treatment.  
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor…  
  • A 10 percent reduction in cancer-related deaths in the U.S. would be worth an estimated $4.4 trillion to current and future generations.